News ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
6.2 ^USD	+2.65%		-0.32%	+37.17%

Apr. 02	ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	CI
Mar. 26	HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	Apr. 02	CI
HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	Mar. 26	MT
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing	Mar. 20	MT
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®	Mar. 11	GL
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam	Mar. 11	CI
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference	Mar. 05	GL
Mizuho Adjusts Price Target on ADMA Biologics to $10 From $9, Maintains Buy Rating	Mar. 01	MT
ADMA Biologics Q4 Net Loss Widens, Revenue Rises; Increases 2024, 2025 Revenue Outlook; Seeks Successor for Chief Financial Officer	Feb. 28	MT
Adma Biologics: Q4 Earnings Snapshot	Feb. 28	AQ
ADMA Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Transcript : ADMA Biologics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q4 Revenue $73.9M, vs. Street Est of $73M	Feb. 28	MT
ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025	Feb. 28	CI
ADMA Biologics Announces CFO Transition	Feb. 28	GL
ADMA Biologics Announces CFO Transition	Feb. 28	AQ
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Feb. 28	GL
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Feb. 28	AQ
ADMA Biologics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024	Feb. 21	GL
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024	Feb. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Summary

Filters